

Wednesday 29th June 2011

**8.30 KEYNOTE:**

From antibodies to engineered fragments and alternative scaffolds with prescribed target specificities and extended plasma-half life.

*Professor. Arne Skerra, Technical University Munchen and XL-protein, Freising, Germany.*

**Single Domain antibodies and fragments.**

*Chairman Professor Arne Skerra*

**8.50** Single domain antibodies-based therapeutics from blocking antibodies to bispecific antibodies.

*Dr. Patrick Chames, INSERM, France.*

**9.10** Making human domain antibodies suitable for systemic treatment.

*Dr. Olga Ignatovich, Manager, Head of dAB discovery, Glaxosmithkline, UK.*

**9.30** In cellulo behaviour of single-chain antibody fragments isolated from intrabody Library.

*Dr. Etienne Weiss, IREBS, University of Strasbourg, France.*

**9.50** Anti-idiotypic antibody fragments mimicking HER2 as vaccines: Immunogenicity and tumour efficacy.

*Dr. Andre Peligrain, INSERM, France.*

**10.10** Exploring novel therapeutic antibodies against c-Met.

*Dr. Joost Neijssen, Genmab, The Netherlands.*

**10.30** Cell-based antibody selection (CBAS™) strategy for generation of fully human antagonistic antibody against GPCRT targets.

*Dr. Sergej M. Kiprijanov, VP Discovery/ research and preclinical developments, Affitech AS, Norway.*

**10.50 REFRESHMENTS AND NETWORKING**

**Engineered Antibodies, Scaffolds and Effector Functions.**

*Dr. Andre Peligrain.*

**11.15** From intracellular antibody fragments to small molecule emulators.

*Professor. Terrence Rabbitts, FRS, Leeds Institute of Molecular Medicine, University of Leeds, UK.*

**11.35** Manufacturing of bispecific DART protein and derivative with extended pk properties  
*Dr. Syd Johnson, VP Antibody engineering, Macrogenics, USA.*

**11.55** Alternative to antibody therapeutics: Bi-specific TCR anti-CD3 fusions for redirected tumour cell killing.

*Dr. Rebecca Ashfield, Immunocore, UK.*

**12.15** The role of Fc dependent antibody effector function in inhibiting metasis and tumorigenesis.

*Dr. Sandra Verploegen, Genmab, The Netherlands.*

**12.35** Preclinical experience with Fc-domain optimized antibodies.

*Dr. Ezio Bonvini, SVP, Macrognics, USA.*

**13.00 LUNCH**

**Novel technologies for Antibody production**

*Dr. Paul Dalby*

**14.00** How single use technologies have influenced and will continue to influence Biopharmaceutical manufacturing.

*Dr. Henry Charlton, Marketing Manager, PallEurope, UK.*

**14.20** A Novel approach to purify monoclonal antibodies: Increased productivity using an integrated process.

*Dr. Lothar Jacob, Merck KGaA, Germany.*

**14.40** Economic advantages of process integration in Mab manufacturing.

*Dr. Richard Shah, Bioprocess Specialist, Palleurope. UK.*

**15.00 CONCLUDES**

**Contact**

Dr. G. Subramanian, 44 Oaken Grove, Maidenhead, Berkshire, SL6 6HH, UK

Tel: +44 (0) 7960 139108

Fax: +44 (0) 1628 671448

Email: [gsub@subramanian.org.uk](mailto:gsub@subramanian.org.uk)

Web: [www.subramanian.org.uk](http://www.subramanian.org.uk)



Produced by Hayward Design & Print • [www.hayward-design.co.uk](http://www.hayward-design.co.uk)

# WORLD BIOPHARM FORUM 2011



BIOPHARMACEUTICAL ANTIBODIES

Robinson College  
Cambridge, UK  
June 28-29, 2011

Please complete the registration form in BLOCK LETTERS and **post** it with full remittance to: Dr. G. Subramanian, 44 Oaken Grove, Maidenhead, Berkshire, SL6 6HH. **or** email to gsub@subramanian.org.uk To reserve your place which will be confirmed upon receipt of your full payment.

Full Name: .....

Job Title:.....

Organisation:.....

Address: .....

..... Postcode: .....

Country:.....

Any Special Requirement: .....

Tel:.....

Fax:.....

Email:.....

**Registration Fees:**

Full attendance including all meals: **£600**  
 Attendance with no accommodation: **£525**

**Method of payment:**

Cheques payable to Dr.G.Subramanian in Pound Sterling only and drawn on a UK based bank. For other method please see www.subramanian.org.uk.

**Cancellation**

Should you be unable to attend, a substitute delegate is welcomed at no extra charge.



12.30 Registration

12.55 Welcome by G.Subramanian

13.00 Plenary Lecture: 30 Years of approved recombinant cell culture products.  
*Dr. William Whitford, Sr Manager, Thermoscientific, USA*

**Advances in Upstream**  
*Chairman, William Whitford*

13.20 New advances in up-stream bioreactors for Mab production.  
*Dr. John Moys, Head of Application Specialists North Europe, Sartorius-Stedim Biotech, UK.*

13.40 Development and scale-up of high titre cell culture process.  
*Dr. Sanjeev Ahuja, Medimmune, USA.*

14.00 Multivariate analysis of CHO based bioprocesses.  
*pD Dr. Dethardt Muller, Dir.Technology Development, Rentschler Biotchnologie GmbH, Lupheim, Germany.*

**Development in Downstream**  
*Richard Francis*

14.20 Innovative technologies for downstream biomanufacturing.  
*Dr. Omar Wahab, Senior process Development specialist, Sartorius-Stedim Biotech, UK.*

14.40 Lowering the production cost of biopharmaceuticals by using fast in process HPLC and multitude disposable columns.  
*Dr. Ales Strancer, CEO BIA Separations, Slovenia.*

15.00 Innovation in monoclonal antibody downstream process development: From platform design to individual separation Unit operation.  
*Dr. Jie Chen, Director Protein Sciences, Dyax Corp, USA.*

15.20 **REFRESHMENTS AND NETWORKING**

**Process Intensification & Product Characterisation**  
*Chairman, Dr. Alahari Arunakumari*

15.50 Efficient integration of upstream and downstream processing using the high yielding PER. C6 cell line production platform.  
*Dr. Marco Cacciuttolo, CEO, Percevia, USA.*

16.10 Effect of bioprocess solution conditions on the structure of antibody.  
*Dr. Paul Dalby, University College London, London.*

16.30 Application of QbD and platform technology to rapid development of antibody therapeutics.  
*Richard Francis, Director, Francis Biopharma, UK.*

16.50 Approaches to polyclonal antibody process for critical therapeutic products.  
*Dr. Chiron Howell, Technical Manager, BTGplc.UK.*

17.10 The characterisation of challenging monoclonal antibody.  
*Dr. Brett Belongia, Senior Manager, EDM, Millipore, USA.*

17.30 Biomanufacturing process of the future.  
*Dipl-Ing. Professor. Florian Grote, Institute for separation and process technology, TU Clausthal, Clausthal-Zerfeld, Germany.*

17.50 Antibody Glycosylation: A practical framework for dealing with it effectively throughout the drug life cycle.  
*Dr. Daryl Fernandes, CEO, Ludger Ltd, UK.*

18.10 Phage display: A proven technology for antibody for antibody discovery.  
*Dr. Andrew E Nixon, VP, Lead discovery and biochemistry, Dyax Corp, USA.*

18.30 Protein precipitation technology for effective integration of high titre upstream and high capacity downstream process.  
*Dr. Alahari Arunakumari, President and Founder, AHABioconsultant LLC, USA.*

**GALA DINNER**